CONTACT US
Home > Inhibitors/Agonists> > Chrysarobin
491-59-8-Chrysarobin Chrysarobin

Chrysarobin

For research use only. Not for therapeutic Use.

  • CAT Number: I024627
  • CAS Number: 491-59-8
  • Molecular Formula: C15H12O3
  • Molecular Weight: 240.26
  • Purity: 98%
Inquiry Now
Related Small Molecules: Cgp 52608     DAAO inhibitor-1     Enoblituzumab    

Chrysarobin is an extract of Goa powder; a complex mixture of reduction products of chrysophanic acid, emodin, and emodin monomethyl ether; used locally in ringworm, psoriasis, and eczema. from NCIt. Chrysophanol-9-anthrone is a member of anthracenes. It derives from an anthralin.


Catalog Number I024627
CAS Number 491-59-8
Synonyms

Chrysarobin; CCRIS5597; CCRIS-5597; CCRIS 5597

Molecular Formula C15H12O3
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name 3-methylanthracene-1,8,9-triol
InChI InChI=1S/C15H12O3/c1-8-5-10-7-9-3-2-4-11(16)13(9)15(18)14(10)12(17)6-8/h2-7,16-18H,1H3
InChIKey JBGKVNQFVAJOGC-UHFFFAOYSA-N
SMILES Cc(cc1O)cc2c1c(O)c(c(O)ccc3)c3c2
Reference

1: BOYMOND P, JADASSOHN W. A propos de la chrysarobine [About chrysarobin]. Dermatologica. 1947;94(4):228-30. French. PMID: 18898893.
2: Kruszewski FH, DiGiovanni J. Alterations in epidermal polyamine levels and DNA synthesis following topical treatment with chrysarobin in SENCAR mice. Cancer Res. 1988 Nov 15;48(22):6390-5. PMID: 3180057.
3: Kruszewski FH, Conti CJ, DiGiovanni J. Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice. Cancer Res. 1987 Jul 15;47(14):3783-90. PMID: 3109733.
4: DiGiovanni J, Decina PC, Prichett WP, Cantor J, Aalfs KK, Coombs MM. Mechanism of mouse skin tumor promotion by chrysarobin. Cancer Res. 1985 Jun;45(6):2584-9. PMID: 3986797.
5: Battalora MS, Conti CJ, Aldaz CM, Slaga TJ, Johnston DA, DiGiovanni J. Regression and progression characteristics of papillomas induced by chrysarobin in SENCAR mice. Carcinogenesis. 1996 May;17(5):955-60. doi: 10.1093/carcin/17.5.955. PMID: 8640943.
6: Battalora MS, Kruszewski FH, DiGiovanni J. Inhibition of chrysarobin skin tumor promotion in SENCAR mice by antioxidants. Carcinogenesis. 1993 Dec;14(12):2507-12. doi: 10.1093/carcin/14.12.2507. PMID: 8269619.
7: DiGiovanni J, Kruszewski FH, Chenicek KJ. Modulation of chrysarobin skin tumor promotion. Carcinogenesis. 1988 Aug;9(8):1445-50. doi: 10.1093/carcin/9.8.1445. PMID: 3135955.
8: NANASI P, KOCSIS A. Beitrag zum Wirkungsmechanismus des Chrysarobins [Pharmacology of chrysarobin]. Dermatol Wochenschr. 1951;124(41):1001-3. Undetermined Language. PMID: 14905945.
9: O’Brien TG, O’Donnell K, Kruszewski FH, DiGiovanni J. Presence of a functionally altered ornithine decarboxylase activity in chrysarobin-promoted mouse epidermal papillomas. Carcinogenesis. 1988 Nov;9(11):2081-5. doi: 10.1093/carcin/9.11.2081. PMID: 3141077.
10: Sehgal VN, Verma P, Khurana A. Anthralin/dithranol in dermatology. Int J Dermatol. 2014 Oct;53(10):e449-60. doi: 10.1111/j.1365-4632.2012.05611.x. Epub 2014 Sep 10. PMID: 25208745.

Request a Quote